The application was supported by data from a phase 1/2, randomized, open-label, 2-way crossover study (NCT03953820) that compared diazepam buccal film with Diastat rectal gel in adult patients on ...

Buprenorphine Buccal Film, which incorporates IntelGenx’s VersaFilm® technology in a novel formulation, is a generic version of Belbuca®, an opioid that is used to manage chronic pain severe ...

Aquestive Therapeutics (AQST) announced the U.S. Food and Drug Administration, FDA, has granted seven years of orphan drug exclusivity, ODE, to Libervant Buccal Film for the acute treatment of ...

Aquestive Therapeutics (NASDAQ:AQST) has received FDA Orphan Drug Exclusivity for its drug Libervant Buccal Film in the treatment of seizure clusters in children aged two to five years, extending ...

Submitted NDA for Libervant™ (diazepam) Buccal Film for treatment of seizure clusters in patients between two and five years of ageAppointed Carl N. Kraus, M.D. as Chief Medical Officer WARREN ...

FDA Acceptance of Libervant™ (diazepam) Buccal Film NDA for treatment of seizure clusters in patients between two and five years of agePrescription Drug User Fee Act (PDUFA) target goal date set ...

Drug delivery company IntelGenx Corp. (OTCQB:IGXT)’s development candidate buprenorphine buccal film, for which an Abbreviated New Drug Application (ANDA) has been filed by Chemo Research SL ...

Background and objectives: Patients with cancer, particularly those undergoing chemotherapy or radiotherapy, may develop oral mucositis. This is the first study to investigate the absorption ...

The buccal film formulation offers a distinct advantage for rapid and convenient administration, even when personnel are wearing protective gear. About Tharimmune, Inc.